Stem Cell LSC inhibitor Set
Axon 5005
CAS [N.A.]
MF #N/AMW #N/A
- Purity:99%
- Soluble in DMSO
Description
A convenient set of BMP inhibitor LDN 193189 hydrochloride (Axon 1509), TGF-beta inhibitor SB 431542 (Axon 1661) and GSK-3 inhibitor CHIR 99021 (Axon 1386) (termed as LSC or LSB/CHIR by their name abbreviation), for differentiation of human pluripotent stem cells (hPSCs). Combining two-factor neuronal programming with small molecule–based inhibition of GSK-3β by CHIR 99021 (2 µM) and SMAD signaling by LDN 193189 (0.5 µM) and SB 431542 (10 µM), converted postnatal human fibroblasts into functional neuron-like cells with yields up to >200% and neuronal purities up to >80%.
LSC (or LSB/CHIR) inhibitor cocktail protocol can be further extended; with adding SU 5402 (Axon 1667) and DAPT (Axon 1484) to form LSB3i, a 5i inhibitor set (Axon 5007), for rapid differentiating hPSCs into nociceptors.
Read more: Additional Product Information
Show all Axon Ligand™Sets
| J. Ladewig et al. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat Methods. 2012, 9, 575-578. |
| S.M. Chambers et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nature Biotechnol. 2012, 30, 715-720. |
List of publications using LDN 193189 hydrochloride (Axon 1509) purchased from Axon Medchem
List of publications using CHIR 99021 (Axon 1386) purchased from Axon Medchem
- Certificate of Analysis
- Material Safety Data Sheet
- Additional Product Information
Chemical name
N.A.
Parent CAS No.
[N.A.]
Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。
暂无问答
本网站将在规定时间内给予删除等相关处理。
